Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Fuji
Express Scripts
Argus Health
Medtronic
Covington
Fish and Richardson
Citi
Baxter
UBS

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,623,826

« Back to Dashboard

Which drugs does patent 8,623,826 protect, and when does it expire?

Patent 8,623,826 protects AKYNZEO and is included in one NDA.

This patent has fifty-three patent family members in thirty-seven countries.
Summary for Patent: 8,623,826
Title:Compositions and methods for treating centrally mediated nausea and vomiting
Abstract: Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.
Inventor(s): Trento; Fabio (Como, IT), Cantoreggi; Sergio (Cagiallo, CH), Rossi; Giorgia (Como, IT), Cannella; Roberta (Varese, IT), Bonadeo; Daniele (Varese, IT)
Assignee: Helsinn Healthcare S.A. (Lugano/Pazallo, CH)
Application Number:13/077,462
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,623,826

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,623,826

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,951,969 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Subscribe
9,186,357 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Subscribe
9,271,975 Compositions and methods for treating centrally mediated nausea and vomiting ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,623,826

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Cyprus 1118062 ➤ Subscribe
Cyprus 1115471 ➤ Subscribe
Denmark 2361090 ➤ Subscribe
Denmark 2722045 ➤ Subscribe
Eurasian Patent Organization 201290356 ➤ Subscribe
Dominican Republic P2012000138 ➤ Subscribe
Eurasian Patent Organization 026815 ➤ Subscribe
Ecuador SP12011907 ➤ Subscribe
European Patent Office 2361090 ➤ Subscribe
European Patent Office 2722044 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Novartis
QuintilesIMS
UBS
Cantor Fitzgerald
US Department of Justice
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot